Every 10-Q that Oaktree Acquisition Corp. III Life Sciences (OACC) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow OACC and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full OACC filings page.
Oaktree Acquisition Corp. III Life Sciences is a Cayman Islands special purpose acquisition company seeking a Business Combination and has not begun operating activities beyond deal search and public company compliance. Total assets were $206.5 million at June 30 2026, including $205.3 million in a U.S. Trust Account invested in interest-bearing deposits.
For the quarter ended June 30 2026, the company reported net income of $1.6 million, and $3.0 million for the six-month period, driven entirely by $3.7 million of interest on Trust Account funds, offset by $0.7 million of general and administrative expenses. Class A ordinary shares subject to possible redemption totaled 19,199,029 at a redemption value of $205.3 million.
Cash outside the Trust Account was $1.18 million with a working capital deficit of $469,905. Management discloses that the need to fund ongoing costs, dependence on potential loans from the Sponsor or others, and the requirement to complete a Business Combination by October 25 2026 (or obtain an extension) raise substantial doubt about the company’s ability to continue as a going concern.
Oaktree Acquisition Corp. III Life Sciences reported net income of $1,394,121 for the quarter ended March 31, 2026, driven by $1,850,659 of interest on cash held in its trust account and offset by $456,538 of general and administrative expenses.
Cash in the trust account reached $203,414,191, reflecting accretion of the redeemable Class A shares to a redemption value of $10.60 per share for 19,199,029 shares. The company held $1,276,930 of cash outside the trust and reported a working capital deficit of $207,947.
The SPAC has not yet selected a business combination target and continues to incur costs pursuing an acquisition. Management discloses that the need for additional capital, the October 25, 2026 deadline to complete a business combination, and the possibility of mandatory liquidation raise substantial doubt about its ability to continue as a going concern.
Oaktree Acquisition Corp. III Life Sciences filed its Q3 2025 10‑Q, showing interest-driven profits while it continues to search for a merger target. Net income was $1,966,742 for the quarter, primarily from $2,192,321 of interest on funds held in trust. For the nine months, net income totaled $5,499,876. Cash held in the Trust Account was $199,769,089 as of September 30, 2025, tied to 19,199,029 Class A shares subject to redemption at $10.41 per share.
Operating cash use was modest, with cash on hand of $1,328,841 and working capital of $254,086. The company remains a SPAC with no revenues before a business combination and faces a deadline of October 25, 2026 to complete a deal. Management disclosed that these conditions raise substantial doubt about its ability to continue as a going concern. As of November 13, 2025, there were 19,783,010 Class A and 4,799,758 Class B shares outstanding, and 3,956,601 warrants in total. The IPO’s over‑allotment was partially exercised, and 231,492 Class B shares were forfeited accordingly.